RecruitingPhase 1NCT07148089
A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
Studying Catecholaminergic polymorphic ventricular tachycardia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Solid Biosciences Inc.
- Intervention
- SGT-501(drug)
- Enrollment
- 18 enrolled
- Eligibility
- 7 years · All sexes
- Timeline
- 2026 – 2031
Study locations (5)
- Boston Children's Hospital, Boston, Massachusetts, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
- St. Paul's Hospital, Vancouver, British Columbia, Canada
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07148089 on ClinicalTrials.govOther trials for Catecholaminergic polymorphic ventricular tachycardia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07263139Safety, Tolerability, and Exploratory Efficacy of AGP100 in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)Agiana Pharmaceuticals
- RECRUITINGPHASE2NCT06658899A Phase 2 Study of CRD-4730 in CPVTCardurion Pharmaceuticals, Inc.
- RECRUITINGNCT06661278Evaluation of Exercise Testing and Physical Activity in Children and Adolescents Living With Inherited ArrhythmiasRoyal Brompton & Harefield NHS Foundation Trust
See all trials for Catecholaminergic polymorphic ventricular tachycardia →